메뉴 건너뛰기




Volumn 10, Issue , 2012, Pages

Novel therapeutic strategies targeting HIV integrase

Author keywords

Crystal structure; Dolutegravir; HIV integrase; Mutations; New drugs; Raltegravir; Resistance

Indexed keywords

ATAZANAVIR; BI C; DOLUTEGRAVIR; EFAVIRENZ; ELVITEGRAVIR; INTEGRASE; L31988; L870812; MK 0536; MK 2048; NEVIRAPINE; RALTEGRAVIR; RIFAMPICIN; UNCLASSIFIED DRUG; INTEGRASE INHIBITOR; INTEGRATION HOST FACTOR;

EID: 84859641222     PISSN: None     EISSN: 17417015     Source Type: Journal    
DOI: 10.1186/1741-7015-10-34     Document Type: Review
Times cited : (62)

References (123)
  • 1
    • 0004131381 scopus 로고    scopus 로고
    • Retroviruses
    • Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press
    • Coffin JM, Hughes SH, Varmus HE. Retroviruses. 1997, Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press.
    • (1997)
    • Coffin, J.M.1    Hughes, S.H.2    Varmus, H.E.3
  • 2
    • 0041420963 scopus 로고    scopus 로고
    • Design and development of integrase inhibitors as anti-HIV agents
    • 10.2174/0929867033456972, 12871104
    • Gupta SP, Nagappa AN. Design and development of integrase inhibitors as anti-HIV agents. Curr Med Chem 2003, 10(18):1779-1794. 10.2174/0929867033456972, 12871104.
    • (2003) Curr Med Chem , vol.10 , Issue.18 , pp. 1779-1794
    • Gupta, S.P.1    Nagappa, A.N.2
  • 3
    • 0036428535 scopus 로고    scopus 로고
    • Modulation of the oligomeric structures of HIV-1 retroviral enzymes by synthetic peptides and small molecules
    • 10.1046/j.1432-1033.2002.03216.x, 12392542
    • Sluis-Cremer N, Tachedjian G. Modulation of the oligomeric structures of HIV-1 retroviral enzymes by synthetic peptides and small molecules. Eur J Biochem 2002, 269(21):5103-5111. 10.1046/j.1432-1033.2002.03216.x, 12392542.
    • (2002) Eur J Biochem , vol.269 , Issue.21 , pp. 5103-5111
    • Sluis-Cremer, N.1    Tachedjian, G.2
  • 4
    • 0042423356 scopus 로고    scopus 로고
    • Structure-activity relationships of HIV-1 integrase inhibitors--enzyme-ligand interactions
    • 10.2174/0929867033456981, 12871105
    • Maurin C, Bailly F, Cotelle P. Structure-activity relationships of HIV-1 integrase inhibitors--enzyme-ligand interactions. Curr Med Chem 2003, 10(18):1795-1810. 10.2174/0929867033456981, 12871105.
    • (2003) Curr Med Chem , vol.10 , Issue.18 , pp. 1795-1810
    • Maurin, C.1    Bailly, F.2    Cotelle, P.3
  • 5
    • 0034899584 scopus 로고    scopus 로고
    • The complestatins as HIV-1 integrase inhibitors. Efficient isolation, structure elucidation, and inhibitory activities of isocomplestatin, chloropeptin I, new complestatins, A and B, and acid-hydrolysis products of chloropeptin I
    • 10.1021/np000632z, 11473415
    • Singh SB, Jayasuriya H, Salituro GM, Zink DL, Shafiee A, Heimbuch B, Silverman KC, Lingham RB, Genilloud O, Teran A, Vilella D, Felock P, Hazuda D. The complestatins as HIV-1 integrase inhibitors. Efficient isolation, structure elucidation, and inhibitory activities of isocomplestatin, chloropeptin I, new complestatins, A and B, and acid-hydrolysis products of chloropeptin I. J Nat Prod 2001, 64(7):874-882. 10.1021/np000632z, 11473415.
    • (2001) J Nat Prod , vol.64 , Issue.7 , pp. 874-882
    • Singh, S.B.1    Jayasuriya, H.2    Salituro, G.M.3    Zink, D.L.4    Shafiee, A.5    Heimbuch, B.6    Silverman, K.C.7    Lingham, R.B.8    Genilloud, O.9    Teran, A.10    Vilella, D.11    Felock, P.12    Hazuda, D.13
  • 6
    • 0035428027 scopus 로고    scopus 로고
    • Rational drug design of DNA oligonucleotides as HIV inhibitors
    • 10.2174/1568005013343173, 12455406
    • Jing N, Xu X. Rational drug design of DNA oligonucleotides as HIV inhibitors. Curr Drug Targets Infect Disord 2001, 1(2):79-90. 10.2174/1568005013343173, 12455406.
    • (2001) Curr Drug Targets Infect Disord , vol.1 , Issue.2 , pp. 79-90
    • Jing, N.1    Xu, X.2
  • 7
    • 33646771890 scopus 로고    scopus 로고
    • Discovery of HIV-1 integrase inhibitors through a novel combination of ligand and structure-based drug design
    • 10.2174/1573406053765440, 16787322
    • Brigo A, Mustata GI, Briggs JM, Moro S. Discovery of HIV-1 integrase inhibitors through a novel combination of ligand and structure-based drug design. Med Chem 2005, 1(3):263-275. 10.2174/1573406053765440, 16787322.
    • (2005) Med Chem , vol.1 , Issue.3 , pp. 263-275
    • Brigo, A.1    Mustata, G.I.2    Briggs, J.M.3    Moro, S.4
  • 8
    • 0041922298 scopus 로고    scopus 로고
    • Peptides as new inhibitors of HIV-1 reverse transcriptase and integrase
    • 10.2174/0929867033457007, 12871103
    • de Soultrait VR, Desjobert C, Tarrago-Litvak L. Peptides as new inhibitors of HIV-1 reverse transcriptase and integrase. Curr Med Chem 2003, 10(18):1765-1778. 10.2174/0929867033457007, 12871103.
    • (2003) Curr Med Chem , vol.10 , Issue.18 , pp. 1765-1778
    • de Soultrait, V.R.1    Desjobert, C.2    Tarrago-Litvak, L.3
  • 10
    • 0036783717 scopus 로고    scopus 로고
    • Inhibition of human immunodeficiency virus type 1 isolates by the integrase inhibitor L-731,988, a diketo Acid
    • 10.1128/AAC.46.10.3301-3303.2002, 128787, 12234866
    • Reinke R, Lee DJ, Robinson WE. Inhibition of human immunodeficiency virus type 1 isolates by the integrase inhibitor L-731,988, a diketo Acid. Antimicrob Agents Chemother 2002, 46(10):3301-3303. 10.1128/AAC.46.10.3301-3303.2002, 128787, 12234866.
    • (2002) Antimicrob Agents Chemother , vol.46 , Issue.10 , pp. 3301-3303
    • Reinke, R.1    Lee, D.J.2    Robinson, W.E.3
  • 11
    • 65249180642 scopus 로고    scopus 로고
    • Emerging pharmacology: inhibitors of human immunodeficiency virus integration
    • 10.1146/annurev.pharmtox.011008.145553, 18928385
    • Hazuda D, Iwamoto M, Wenning L. Emerging pharmacology: inhibitors of human immunodeficiency virus integration. Annu Rev Pharmacol Toxicol 2009, 49:377-394. 10.1146/annurev.pharmtox.011008.145553, 18928385.
    • (2009) Annu Rev Pharmacol Toxicol , vol.49 , pp. 377-394
    • Hazuda, D.1    Iwamoto, M.2    Wenning, L.3
  • 12
    • 0037066730 scopus 로고    scopus 로고
    • Structural determinants for HIV-1 integrase inhibition by beta-diketo acids
    • 10.1074/jbc.M110758200, 11805103
    • Marchand C, Zhang X, Pais GC, Cowansage K, Neamati N, Burke TR, Pommier Y. Structural determinants for HIV-1 integrase inhibition by beta-diketo acids. J Biol Chem 2002, 277(15):12596-12603. 10.1074/jbc.M110758200, 11805103.
    • (2002) J Biol Chem , vol.277 , Issue.15 , pp. 12596-12603
    • Marchand, C.1    Zhang, X.2    Pais, G.C.3    Cowansage, K.4    Neamati, N.5    Burke, T.R.6    Pommier, Y.7
  • 13
    • 13044295993 scopus 로고    scopus 로고
    • Structure of the HIV-1 integrase catalytic domain complexed with an inhibitor: a platform for antiviral drug design
    • 10.1073/pnas.96.23.13040, 23896, 10557269
    • Goldgur Y, Craigie R, Cohen GH, Fujiwara T, Yoshinaga T, Fujishita T, Sugimoto H, Endo T, Murai H, Davies DR. Structure of the HIV-1 integrase catalytic domain complexed with an inhibitor: a platform for antiviral drug design. Proc Natl Acad Sci USA 1999, 96(23):13040-13043. 10.1073/pnas.96.23.13040, 23896, 10557269.
    • (1999) Proc Natl Acad Sci USA , vol.96 , Issue.23 , pp. 13040-13043
    • Goldgur, Y.1    Craigie, R.2    Cohen, G.H.3    Fujiwara, T.4    Yoshinaga, T.5    Fujishita, T.6    Sugimoto, H.7    Endo, T.8    Murai, H.9    Davies, D.R.10
  • 14
    • 84860681023 scopus 로고    scopus 로고
    • Derwent Abstract No. 1999-580735/49, "New indole derivatives are integrase inhibitors useful as antiviral and anit-HIV agents"
    • Derwent Abstract No. 1999-580735/49, "New indole derivatives are integrase inhibitors useful as antiviral and anit-HIV agents". abstract of WO 99/50245 Shionogi & Co, Ltd 1999,
    • (1999) abstract of WO 99/50245 Shionogi & Co, Ltd
  • 15
    • 1542286600 scopus 로고    scopus 로고
    • Enzymology of a carbonyl reduction clearance pathway for the HIV integrase inhibitor, S-1360: role of human liver cytosolic aldo-keto reductases
    • 10.1016/j.cbi.2003.12.001, 15013815
    • Rosemond MJ, St John-Williams L, Yamaguchi T, Fujishita T, Walsh JS. Enzymology of a carbonyl reduction clearance pathway for the HIV integrase inhibitor, S-1360: role of human liver cytosolic aldo-keto reductases. Chem Biol Interact 2004, 147(2):129-139. 10.1016/j.cbi.2003.12.001, 15013815.
    • (2004) Chem Biol Interact , vol.147 , Issue.2 , pp. 129-139
    • Rosemond, M.J.1    St John-Williams, L.2    Yamaguchi, T.3    Fujishita, T.4    Walsh, J.S.5
  • 16
    • 77951672581 scopus 로고    scopus 로고
    • FDA notifications. FDA approves raltegravir for HIV-1 treatment-naive patients
    • FDA notifications. FDA approves raltegravir for HIV-1 treatment-naive patients. AIDS Alert 2009, 24(9):106-107.
    • (2009) AIDS Alert , vol.24 , Issue.9 , pp. 106-107
  • 18
    • 77149154319 scopus 로고    scopus 로고
    • Stage-dependent inhibition of HIV-1 replication by antiretroviral drugs in cell culture
    • 10.1128/AAC.01537-09, 2826010, 20038621
    • Donahue DA, Sloan RD, Kuhl BD, Bar-Magen T, Schader SM, Wainberg MA. Stage-dependent inhibition of HIV-1 replication by antiretroviral drugs in cell culture. Antimicrob Agents Chemother 2010, 54(3):1047-1054. 10.1128/AAC.01537-09, 2826010, 20038621.
    • (2010) Antimicrob Agents Chemother , vol.54 , Issue.3 , pp. 1047-1054
    • Donahue, D.A.1    Sloan, R.D.2    Kuhl, B.D.3    Bar-Magen, T.4    Schader, S.M.5    Wainberg, M.A.6
  • 19
    • 34147136222 scopus 로고    scopus 로고
    • Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial
    • 10.1016/S0140-6736(07)60597-2, 17434401, Protocol 005 Team
    • Grinsztejn B, Nguyen BY, Katlama C, Gatell JM, Lazzarin A, Vittecoq D, Gonzalez CJ, Chen J, Harvey CM, Isaacs RD, . Protocol 005 Team Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial. Lancet 2007, 369(9569):1261-1269. 10.1016/S0140-6736(07)60597-2, 17434401, Protocol 005 Team.
    • (2007) Lancet , vol.369 , Issue.9569 , pp. 1261-1269
    • Grinsztejn, B.1    Nguyen, B.Y.2    Katlama, C.3    Gatell, J.M.4    Lazzarin, A.5    Vittecoq, D.6    Gonzalez, C.J.7    Chen, J.8    Harvey, C.M.9    Isaacs, R.D.10
  • 21
    • 34748860363 scopus 로고    scopus 로고
    • Rapid and durable antiretroviral effect of the HIV-1 Integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: results of a 48-week controlled study
    • 10.1097/QAI.0b013e318157131c, 17721395, Protocol 004 Part II Study Team
    • Markowitz M, Nguyen BY, Gotuzzo E, Mendo F, Ratanasuwan W, Kovacs C, Prada G, Morales-Ramirez JO, Crumpacker CS, Isaacs RD, Gilde LR, Wan H, Miller MD, Wenning LA, Teppler H, . Protocol 004 Part II Study Team Rapid and durable antiretroviral effect of the HIV-1 Integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: results of a 48-week controlled study. J Acquir Immune Defic Syndr 2007, 46(2):125-133. 10.1097/QAI.0b013e318157131c, 17721395, Protocol 004 Part II Study Team.
    • (2007) J Acquir Immune Defic Syndr , vol.46 , Issue.2 , pp. 125-133
    • Markowitz, M.1    Nguyen, B.Y.2    Gotuzzo, E.3    Mendo, F.4    Ratanasuwan, W.5    Kovacs, C.6    Prada, G.7    Morales-Ramirez, J.O.8    Crumpacker, C.S.9    Isaacs, R.D.10    Gilde, L.R.11    Wan, H.12    Miller, M.D.13    Wenning, L.A.14    Teppler, H.15
  • 24
    • 77950310177 scopus 로고    scopus 로고
    • Raltegravir: is a 400 mg once-daily dose enough?
    • 10.1093/jac/dkp488, 20071368
    • Lanzafame M, Hill A, Lattuada E, Calcagno A, Bonora S. Raltegravir: is a 400 mg once-daily dose enough?. J Antimicrob Chemother 2010, 65(3):595-597. 10.1093/jac/dkp488, 20071368.
    • (2010) J Antimicrob Chemother , vol.65 , Issue.3 , pp. 595-597
    • Lanzafame, M.1    Hill, A.2    Lattuada, E.3    Calcagno, A.4    Bonora, S.5
  • 27
    • 77956228894 scopus 로고    scopus 로고
    • HIV-1 subtype B and C integrase enzymes exhibit differential patterns of resistance to integrase inhibitors in biochemical assays
    • 10.1097/QAD.0b013e32833cf265, 20647908
    • Bar-Magen T, Donahue DA, McDonough EI, Kuhl BD, Faltenbacher VH, Xu H, Michaud V, Sloan RD, Wainberg MA. HIV-1 subtype B and C integrase enzymes exhibit differential patterns of resistance to integrase inhibitors in biochemical assays. AIDS 2010, 24(14):2171-2179. 10.1097/QAD.0b013e32833cf265, 20647908.
    • (2010) AIDS , vol.24 , Issue.14 , pp. 2171-2179
    • Bar-Magen, T.1    Donahue, D.A.2    McDonough, E.I.3    Kuhl, B.D.4    Faltenbacher, V.H.5    Xu, H.6    Michaud, V.7    Sloan, R.D.8    Wainberg, M.A.9
  • 28
    • 62149093020 scopus 로고    scopus 로고
    • The G140S mutation in HIV integrases from raltegravir-resistant patients rescues catalytic defect due to the resistance Q148H mutation
    • 2651800, 19129221
    • Delelis O, Malet I, Na L, Tchertanov L, Calvez V, Marcelin AG, Subra F, Deprez E, Mouscadet JF. The G140S mutation in HIV integrases from raltegravir-resistant patients rescues catalytic defect due to the resistance Q148H mutation. Nucleic Acids Res 2009, 37(4):1193-1201. 2651800, 19129221.
    • (2009) Nucleic Acids Res , vol.37 , Issue.4 , pp. 1193-1201
    • Delelis, O.1    Malet, I.2    Na, L.3    Tchertanov, L.4    Calvez, V.5    Marcelin, A.G.6    Subra, F.7    Deprez, E.8    Mouscadet, J.F.9
  • 30
    • 77957310350 scopus 로고    scopus 로고
    • Effect of raltegravir resistance mutations in HIV-1 integrase on viral fitness
    • 10.1097/QAI.0b013e3181e9a87a, 2943977, 20634701
    • Hu Z, Kuritzkes DR. Effect of raltegravir resistance mutations in HIV-1 integrase on viral fitness. J Acquir Immune Defic Syndr 2010, 55(2):148-155. 10.1097/QAI.0b013e3181e9a87a, 2943977, 20634701.
    • (2010) J Acquir Immune Defic Syndr , vol.55 , Issue.2 , pp. 148-155
    • Hu, Z.1    Kuritzkes, D.R.2
  • 33
    • 79954626457 scopus 로고    scopus 로고
    • HIV-1 integrase inhibitor resistance and its clinical implications
    • 10.1093/infdis/jir025, 3069732, 21459813
    • Blanco JL, Varghese V, Rhee SY, Gatell JM, Shafer RW. HIV-1 integrase inhibitor resistance and its clinical implications. J Infect Dis 2011, 203(9):1204-1214. 10.1093/infdis/jir025, 3069732, 21459813.
    • (2011) J Infect Dis , vol.203 , Issue.9 , pp. 1204-1214
    • Blanco, J.L.1    Varghese, V.2    Rhee, S.Y.3    Gatell, J.M.4    Shafer, R.W.5
  • 35
    • 62249163679 scopus 로고    scopus 로고
    • Elvitegravir, an oral HIV integrase inhibitor, for the potential treatment of HIV infection
    • Klibanov OM. Elvitegravir, an oral HIV integrase inhibitor, for the potential treatment of HIV infection. Curr Opin Investig Drugs 2009, 10(2):190-200.
    • (2009) Curr Opin Investig Drugs , vol.10 , Issue.2 , pp. 190-200
    • Klibanov, O.M.1
  • 37
    • 84860686661 scopus 로고    scopus 로고
    • Antiretroviral Agents in Development
    • DeJesus E. Antiretroviral Agents in Development. , http://www.thebody.com/content/art1352.html
    • DeJesus, E.1
  • 38
    • 77954069487 scopus 로고    scopus 로고
    • Single-tablet quad regimen achieves high rate of virologic suppression
    • Annonymous
    • Annonymous Single-tablet quad regimen achieves high rate of virologic suppression. AIDS Patient Care STDS 2010, 24(3):197. Annonymous.
    • (2010) AIDS Patient Care STDS , vol.24 , Issue.3 , pp. 197
  • 39
    • 79952077699 scopus 로고    scopus 로고
    • Clinical pharmacokinetic and pharmacodynamic profile of the HIV integrase inhibitor elvitegravir
    • 10.2165/11584570-000000000-00000, 21348537
    • Ramanathan S, Mathias AA, German P, Kearney BP. Clinical pharmacokinetic and pharmacodynamic profile of the HIV integrase inhibitor elvitegravir. Clin Pharmacokinet 2011, 50(4):229-244. 10.2165/11584570-000000000-00000, 21348537.
    • (2011) Clin Pharmacokinet , vol.50 , Issue.4 , pp. 229-244
    • Ramanathan, S.1    Mathias, A.A.2    German, P.3    Kearney, B.P.4
  • 40
    • 57749197592 scopus 로고    scopus 로고
    • Dose-response of ritonavir on hepatic CYP3A activity and elvitegravir oral exposure
    • 10.1038/clpt.2008.168, 18815591
    • Mathias AA, West S, Hui J, Kearney BP. Dose-response of ritonavir on hepatic CYP3A activity and elvitegravir oral exposure. Clin Pharmacol Ther 2009, 85(1):64-70. 10.1038/clpt.2008.168, 18815591.
    • (2009) Clin Pharmacol Ther , vol.85 , Issue.1 , pp. 64-70
    • Mathias, A.A.1    West, S.2    Hui, J.3    Kearney, B.P.4
  • 41
    • 33748113778 scopus 로고    scopus 로고
    • Antiviral Activity, Pharmacokinetics, and Dose Response of the HIV-1 Integrase Inhibitor GS-9137 (JTK-303) in Treatment-Naive and Treatment-Experienced Patients
    • 10.1097/01.qai.0000233308.82860.2f, 16936557, The 183-Study Team
    • DeJesus E, Berger D, Markowitz M, Cohen C, Hawkins T, Ruane P, Elion R, Farthing C, Zhong L, Cheng AK, . The 183-Study Team Antiviral Activity, Pharmacokinetics, and Dose Response of the HIV-1 Integrase Inhibitor GS-9137 (JTK-303) in Treatment-Naive and Treatment-Experienced Patients. JAIDS 2006, 43(1):1-5. 10.1097/01.qai.0000233308.82860.2f, 16936557, The 183-Study Team.
    • (2006) JAIDS , vol.43 , Issue.1 , pp. 1-5
    • DeJesus, E.1    Berger, D.2    Markowitz, M.3    Cohen, C.4    Hawkins, T.5    Ruane, P.6    Elion, R.7    Farthing, C.8    Zhong, L.9    Cheng, A.K.10
  • 42
    • 84860686663 scopus 로고    scopus 로고
    • Elvitegravir "Quad" Single-tablet Regimen Shows Continued HIV Suppression at 48 Weeks
    • Highleyman L. Elvitegravir "Quad" Single-tablet Regimen Shows Continued HIV Suppression at 48 Weeks. , http://www.hivandhepatitis.com/2010_conference/icaac/docs/0914_a.html
    • Highleyman, L.1
  • 43
    • 77749267991 scopus 로고    scopus 로고
    • Activity of elvitegravir, a once-daily integrase inhibitor, against resistant HIV Type 1: results of a phase 2, randomized, controlled, dose-ranging clinical trial
    • 10.1086/650698, 20146631
    • Zolopa AR, Berger DS, Lampiris H, Zhong L, Chuck SL, Enejosa JV, Kearney BP, Cheng AK. Activity of elvitegravir, a once-daily integrase inhibitor, against resistant HIV Type 1: results of a phase 2, randomized, controlled, dose-ranging clinical trial. J Infect Dis 2010, 201(6):814-822. 10.1086/650698, 20146631.
    • (2010) J Infect Dis , vol.201 , Issue.6 , pp. 814-822
    • Zolopa, A.R.1    Berger, D.S.2    Lampiris, H.3    Zhong, L.4    Chuck, S.L.5    Enejosa, J.V.6    Kearney, B.P.7    Cheng, A.K.8
  • 45
    • 80055028058 scopus 로고    scopus 로고
    • Efficacy of a nucleoside-sparing regimen of darunavir/ritonavir plus raltegravir in treatment-naïve HIV-1-infected patients (ACTG A5262)
    • 10.1097/QAD.0b013e32834bbaa9, 21857490, ACTG A5262 Team
    • Taiwo B, Zheng L, Gallien S, Matining RM, Kuritzkes DR, Wilson CC, Berzins BI, Acosta EP, Bastow B, Kim PS, Eron JJ, . ACTG A5262 Team Efficacy of a nucleoside-sparing regimen of darunavir/ritonavir plus raltegravir in treatment-naïve HIV-1-infected patients (ACTG A5262). AIDS 2011, 25(17):2113-2122. 10.1097/QAD.0b013e32834bbaa9, 21857490, ACTG A5262 Team.
    • (2011) AIDS , vol.25 , Issue.17 , pp. 2113-2122
    • Taiwo, B.1    Zheng, L.2    Gallien, S.3    Matining, R.M.4    Kuritzkes, D.R.5    Wilson, C.C.6    Berzins, B.I.7    Acosta, E.P.8    Bastow, B.9    Kim, P.S.10    Eron, J.J.11
  • 46
    • 79957668616 scopus 로고    scopus 로고
    • Elvitegravir overcomes resistance to raltegravir induced by integrase mutation Y143
    • 10.1097/QAD.0b013e3283473599, 21505303
    • Métifiot M, Vandegraaff N, Maddali K, Naumova A, Zhang X, Rhodes D, Marchand C, Pommier Y. Elvitegravir overcomes resistance to raltegravir induced by integrase mutation Y143. AIDS 2011, 25(9):1175-1178. 10.1097/QAD.0b013e3283473599, 21505303.
    • (2011) AIDS , vol.25 , Issue.9 , pp. 1175-1178
    • Métifiot, M.1    Vandegraaff, N.2    Maddali, K.3    Naumova, A.4    Zhang, X.5    Rhodes, D.6    Marchand, C.7    Pommier, Y.8
  • 47
    • 37849002059 scopus 로고    scopus 로고
    • Broad antiretroviral activity and resistance profile of the novel human immunodeficiency virus integrase inhibitor elvitegravir (JTK-303/GS-9137)
    • 10.1128/JVI.01534-07, 2224569, 17977962
    • Shimura K, Kodama E, Sakagami Y, Matsuzaki Y, Watanabe W, Yamataka K, Watanabe Y, Ohata Y, Doi S, Sato M, Kano M, Ikeda S, Matsuoka M. Broad antiretroviral activity and resistance profile of the novel human immunodeficiency virus integrase inhibitor elvitegravir (JTK-303/GS-9137). J Virol 2008, 82(2):764-774. 10.1128/JVI.01534-07, 2224569, 17977962.
    • (2008) J Virol , vol.82 , Issue.2 , pp. 764-774
    • Shimura, K.1    Kodama, E.2    Sakagami, Y.3    Matsuzaki, Y.4    Watanabe, W.5    Yamataka, K.6    Watanabe, Y.7    Ohata, Y.8    Doi, S.9    Sato, M.10    Kano, M.11    Ikeda, S.12    Matsuoka, M.13
  • 48
    • 53049101908 scopus 로고    scopus 로고
    • Biochemical analysis of HIV-1 integrase variants resistant to strand transfer inhibitors
    • 10.1074/jbc.M804213200, 3259799, 18577511
    • Dicker IB, Terry B, Lin Z, Li Z, Bollini S, Samanta HK, Gali V, Walker MA, Krystal MR. Biochemical analysis of HIV-1 integrase variants resistant to strand transfer inhibitors. J Biol Chem 2008, 283(35):23599-23609. 10.1074/jbc.M804213200, 3259799, 18577511.
    • (2008) J Biol Chem , vol.283 , Issue.35 , pp. 23599-23609
    • Dicker, I.B.1    Terry, B.2    Lin, Z.3    Li, Z.4    Bollini, S.5    Samanta, H.K.6    Gali, V.7    Walker, M.A.8    Krystal, M.R.9
  • 49
    • 73549123203 scopus 로고    scopus 로고
    • Strand transfer inhibitors of HIV-1 integrase: bringing in a new era of antiretroviral therapy
    • 10.1016/j.antiviral.2009.11.004, 19925830
    • McColl DJ, Chen X. Strand transfer inhibitors of HIV-1 integrase: bringing in a new era of antiretroviral therapy. Antivir Res 2010, 85:101-18. 10.1016/j.antiviral.2009.11.004, 19925830.
    • (2010) Antivir Res , vol.85 , pp. 101-118
    • McColl, D.J.1    Chen, X.2
  • 50
    • 62349120391 scopus 로고    scopus 로고
    • Dynamic patterns of human immunodeficiency virus type 1 integrase gene evolution in patients failing raltegravir-based salvage therapies
    • 10.1097/QAD.0b013e328323da60, 19165083
    • Canducci F, Sampaolo M, Marinozzi MC, Boeri E, Spagnuolo V, Galli A, Castagna A, Lazzarin A, Clementi M, Gianotti N. Dynamic patterns of human immunodeficiency virus type 1 integrase gene evolution in patients failing raltegravir-based salvage therapies. AIDS 2009, 23(4):455-460. 10.1097/QAD.0b013e328323da60, 19165083.
    • (2009) AIDS , vol.23 , Issue.4 , pp. 455-460
    • Canducci, F.1    Sampaolo, M.2    Marinozzi, M.C.3    Boeri, E.4    Spagnuolo, V.5    Galli, A.6    Castagna, A.7    Lazzarin, A.8    Clementi, M.9    Gianotti, N.10
  • 51
    • 46949098038 scopus 로고    scopus 로고
    • Anti-infectives: clinical progress of HIV-1 integrase inhibitors
    • 10.1517/14728214.13.2.213, 18537517
    • Al-Mawsawi LQ, Al-Safi RI, Neamati N. Anti-infectives: clinical progress of HIV-1 integrase inhibitors. Expert Opin Emerg Drugs 2008, 13(2):213-225. 10.1517/14728214.13.2.213, 18537517.
    • (2008) Expert Opin Emerg Drugs , vol.13 , Issue.2 , pp. 213-225
    • Al-Mawsawi, L.Q.1    Al-Safi, R.I.2    Neamati, N.3
  • 52
    • 84860686656 scopus 로고    scopus 로고
    • Discovery of MK-2048 - subtle changes confer unique resistance properties to a series of tricyclic hydroxypyrrole integrase strand transfer inhibitor
    • Vacca J, Wai J, Fisher T, Embrey M, Hazuda D, Miller M, Felock P, Witmer M, Gabryelski L, Lyle T. Discovery of MK-2048 - subtle changes confer unique resistance properties to a series of tricyclic hydroxypyrrole integrase strand transfer inhibitor. , http://www.ias2007.org/pag/Abstracts.aspx?AID=3234
    • Vacca, J.1    Wai, J.2    Fisher, T.3    Embrey, M.4    Hazuda, D.5    Miller, M.6    Felock, P.7    Witmer, M.8    Gabryelski, L.9    Lyle, T.10
  • 53
    • 78650640149 scopus 로고    scopus 로고
    • Cross-resistance profile determination of two second-generation HIV-1 integrase inhibitors using a panel of recombinant viruses derived from raltegravir-treated clinical isolates
    • 10.1128/AAC.01733-09, 3019647, 20956600
    • Van Wesenbeeck L, Rondelez E, Feyaerts M, Verheyen A, Van der Borght K, Smits V, Cleybergh C, De Wolf H, Van Baelen K, Stuyver LJ. Cross-resistance profile determination of two second-generation HIV-1 integrase inhibitors using a panel of recombinant viruses derived from raltegravir-treated clinical isolates. Antimicrob Agents Chemother 2011, 55(1):321-325. 10.1128/AAC.01733-09, 3019647, 20956600.
    • (2011) Antimicrob Agents Chemother , vol.55 , Issue.1 , pp. 321-325
    • Van Wesenbeeck, L.1    Rondelez, E.2    Feyaerts, M.3    Verheyen, A.4    Van der Borght, K.5    Smits, V.6    Cleybergh, C.7    De Wolf, H.8    Van Baelen, K.9    Stuyver, L.J.10
  • 54
    • 77957096837 scopus 로고    scopus 로고
    • Physical trapping of HIV-1 synaptic complex by different structural classes of integrase strand transfer inhibitors
    • 10.1021/bi100514s, 2965028, 20799722
    • Pandey KK, Bera S, Vora AC, Grandgenett DP. Physical trapping of HIV-1 synaptic complex by different structural classes of integrase strand transfer inhibitors. Biochemistry 2010, 49(38):8376-8387. 10.1021/bi100514s, 2965028, 20799722.
    • (2010) Biochemistry , vol.49 , Issue.38 , pp. 8376-8387
    • Pandey, K.K.1    Bera, S.2    Vora, A.C.3    Grandgenett, D.P.4
  • 56
    • 77956017859 scopus 로고    scopus 로고
    • Identification of novel mutations responsible for resistance to MK-2048, a second-generation HIV-1 integrase inhibitor
    • 10.1128/JVI.01164-10, 2937597, 20610719
    • Bar-Magen T, Sloan RD, Donahue DA, Kuhl BD, Zabeida A, Xu H, Oliveira M, Hazuda DJ, Wainberg MA. Identification of novel mutations responsible for resistance to MK-2048, a second-generation HIV-1 integrase inhibitor. J Virol 2010, 84(18):9210-9216. 10.1128/JVI.01164-10, 2937597, 20610719.
    • (2010) J Virol , vol.84 , Issue.18 , pp. 9210-9216
    • Bar-Magen, T.1    Sloan, R.D.2    Donahue, D.A.3    Kuhl, B.D.4    Zabeida, A.5    Xu, H.6    Oliveira, M.7    Hazuda, D.J.8    Wainberg, M.A.9
  • 57
    • 84860686658 scopus 로고    scopus 로고
    • Raltegravir shows promise as a PREP drug
    • Raltegravir shows promise as a PREP drug. , http://www.aidsmap.com/Raltegravir-shows-potential-for-use-as-PrEP-drug/page/1434320/
  • 58
    • 79955546176 scopus 로고    scopus 로고
    • Integrase inhibitors effective against human T-cell leukemia virus type 1
    • 10.1128/AAC.01413-10, 3088187, 21343468
    • Seegulam ME, Ratner L. Integrase inhibitors effective against human T-cell leukemia virus type 1. Antimicrob Agents Chemother 2011, 55(5):2011-2017. 10.1128/AAC.01413-10, 3088187, 21343468.
    • (2011) Antimicrob Agents Chemother , vol.55 , Issue.5 , pp. 2011-2017
    • Seegulam, M.E.1    Ratner, L.2
  • 62
    • 79959695256 scopus 로고    scopus 로고
    • The role of unintegrated DNA in HIV infection
    • 10.1186/1742-4690-8-52, 3148978, 21722380
    • Sloan RD, Wainberg MA. The role of unintegrated DNA in HIV infection. Retrovirology 2011, 8:52. 10.1186/1742-4690-8-52, 3148978, 21722380.
    • (2011) Retrovirology , vol.8 , pp. 52
    • Sloan, R.D.1    Wainberg, M.A.2
  • 63
    • 84860686659 scopus 로고    scopus 로고
    • S/GSK1349572 Is a Potent Next Generation HIV Integrase Inhibitor and Demonstrates a Superior Resistance Profile Substantiated with 60 Integrase Mutant Molecular Clones
    • Seki TKM, Wakasa-Morimoto C, Yoshinaga T, Sato A, Fujiwara T, Underwood M, Garvey EP, Johns BA. S/GSK1349572 Is a Potent Next Generation HIV Integrase Inhibitor and Demonstrates a Superior Resistance Profile Substantiated with 60 Integrase Mutant Molecular Clones. , http://www.retroconference.org/2010/Abstracts/38374.htm
    • Seki, T.K.M.1    Wakasa-Morimoto, C.2    Yoshinaga, T.3    Sato, A.4    Fujiwara, T.5    Underwood, M.6    Garvey, E.P.7    Johns, B.A.8
  • 64
    • 73549088975 scopus 로고    scopus 로고
    • S/GSK1349572: a next generation integrase inhibitor with activity against integrase inhibitor-resistant clinical isolates from patients experiencing virologic failure while on raltegravir therapy
    • Levin: Conference Reports for NATAP, 2880256, 20519026
    • Underwood M, Johns B, Sato A, Fujiwara T, Spreen W. S/GSK1349572: a next generation integrase inhibitor with activity against integrase inhibitor-resistant clinical isolates from patients experiencing virologic failure while on raltegravir therapy. 5th International AIDS Society's Conference on HIV Pathogenesis, Cape Town, South Africa 2009 2009, Levin: Conference Reports for NATAP, 2880256, 20519026., http://www.natap.org/2009/IAS/IAS_06.htm
    • (2009) 5th International AIDS Society's Conference on HIV Pathogenesis, Cape Town, South Africa 2009
    • Underwood, M.1    Johns, B.2    Sato, A.3    Fujiwara, T.4    Spreen, W.5
  • 66
    • 73849124557 scopus 로고    scopus 로고
    • Pharmacokinetics and safety of S/GSK1349572, a next-generation HIV integrase inhibitor, in healthy volunteers
    • 10.1128/AAC.00842-09, 2798521, 19884365
    • Min S, Song I, Borland J, Chen S, Lou Y, Fujiwara T, Piscitelli SC. Pharmacokinetics and safety of S/GSK1349572, a next-generation HIV integrase inhibitor, in healthy volunteers. Antimicrob Agents Chemother 2010, 54(1):254-258. 10.1128/AAC.00842-09, 2798521, 19884365.
    • (2010) Antimicrob Agents Chemother , vol.54 , Issue.1 , pp. 254-258
    • Min, S.1    Song, I.2    Borland, J.3    Chen, S.4    Lou, Y.5    Fujiwara, T.6    Piscitelli, S.C.7
  • 68
    • 80052399651 scopus 로고    scopus 로고
    • Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of dolutegravir as 10-day monotherapy in HIV-1-infected adults
    • 10.1097/QAD.0b013e32834a1dd9, 21716073
    • Min S, Sloan L, Dejesus E, Hawkins T, McCurdy L, Song I, Stroder R, Chen S, Underwood M, Fujiwara T, Piscitelli S, Lalezari J. Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of dolutegravir as 10-day monotherapy in HIV-1-infected adults. AIDS 2011, 25(14):1737-1745. 10.1097/QAD.0b013e32834a1dd9, 21716073.
    • (2011) AIDS , vol.25 , Issue.14 , pp. 1737-1745
    • Min, S.1    Sloan, L.2    Dejesus, E.3    Hawkins, T.4    McCurdy, L.5    Song, I.6    Stroder, R.7    Chen, S.8    Underwood, M.9    Fujiwara, T.10    Piscitelli, S.11    Lalezari, J.12
  • 70
    • 84860681017 scopus 로고    scopus 로고
    • Gilead Integrase Inhibitor Outdoes New PIs in Salvage Therapy
    • Mascolini M. Gilead Integrase Inhibitor Outdoes New PIs in Salvage Therapy. , http://www.natap.org/2007/CROI/croi_29.htm
    • Mascolini, M.1
  • 71
    • 84863393356 scopus 로고    scopus 로고
    • Characterization of the R263K mutation in HIV-1 integrase that confers low-level resistance to the second-generation integrase strand transfer inhibitor dolutegravir
    • 10.1128/JVI.06591-11, 22205735
    • Quashie PK, Mesplède T, Han YS, Oliveira M, Singhroy DN, Fujiwara T, Underwood MR, Wainberg MA. Characterization of the R263K mutation in HIV-1 integrase that confers low-level resistance to the second-generation integrase strand transfer inhibitor dolutegravir. J Virol 2012, 86(5):2696-2705. 10.1128/JVI.06591-11, 22205735.
    • (2012) J Virol , vol.86 , Issue.5 , pp. 2696-2705
    • Quashie, P.K.1    Mesplède, T.2    Han, Y.S.3    Oliveira, M.4    Singhroy, D.N.5    Fujiwara, T.6    Underwood, M.R.7    Wainberg, M.A.8
  • 72
    • 80052847754 scopus 로고    scopus 로고
    • Dolutegravir (S/GSK1349572) exhibits significantly slower dissociation than raltegravir and elvitegravir from wild-type and integrase inhibitor-resistant HIV-1 integrase-DNA complexes
    • 10.1128/AAC.00157-11, 3187001, 21807982
    • Hightower KE, Wang R, Deanda F, Johns BA, Weaver K, Shen Y, Tomberlin GH, Carter HL, Broderick T, Sigethy S, Seki T, Kobayashi M, Underwood MR. Dolutegravir (S/GSK1349572) exhibits significantly slower dissociation than raltegravir and elvitegravir from wild-type and integrase inhibitor-resistant HIV-1 integrase-DNA complexes. Antimicrob Agents Chemother 2011, 55(10):4552-4559. 10.1128/AAC.00157-11, 3187001, 21807982.
    • (2011) Antimicrob Agents Chemother , vol.55 , Issue.10 , pp. 4552-4559
    • Hightower, K.E.1    Wang, R.2    Deanda, F.3    Johns, B.A.4    Weaver, K.5    Shen, Y.6    Tomberlin, G.H.7    Carter, H.L.8    Broderick, T.9    Sigethy, S.10    Seki, T.11    Kobayashi, M.12    Underwood, M.R.13
  • 73
    • 84860654621 scopus 로고    scopus 로고
    • Merck Offers Unique Perspective on Second-Generation Integrase Inhibitor
    • Mascolini M. Merck Offers Unique Perspective on Second-Generation Integrase Inhibitor. , http://www.natap.org/2009/PK/PK_10.htm
    • Mascolini, M.1
  • 74
    • 80052847538 scopus 로고    scopus 로고
    • Structural and functional analyses of the second-generation integrase strand transfer inhibitor dolutegravir (S/GSK1349572)
    • 10.1124/mol.111.073189, 3187526, 21719464
    • Hare S, Smith SJ, Métifiot M, Jaxa-Chamiec A, Pommier Y, Hughes SH, Cherepanov P. Structural and functional analyses of the second-generation integrase strand transfer inhibitor dolutegravir (S/GSK1349572). Mol Pharmacol 2011, 80(4):565-572. 10.1124/mol.111.073189, 3187526, 21719464.
    • (2011) Mol Pharmacol , vol.80 , Issue.4 , pp. 565-572
    • Hare, S.1    Smith, S.J.2    Métifiot, M.3    Jaxa-Chamiec, A.4    Pommier, Y.5    Hughes, S.H.6    Cherepanov, P.7
  • 75
    • 79953882562 scopus 로고    scopus 로고
    • Resistance associated mutations to dolutegravir (S/GSK1349572) in HIV-infected patients - impact of HIV subtypes and prior raltegravir experience
    • 10.1016/j.antiviral.2011.03.178, 21439330
    • Garrido C, Soriano V, Geretti AM, Zahonero N, Garcia S, Booth C, Gutierrez F, Viciana I, de Mendoza C. Resistance associated mutations to dolutegravir (S/GSK1349572) in HIV-infected patients - impact of HIV subtypes and prior raltegravir experience. Antiviral Res 2011, 90(3):164-167. 10.1016/j.antiviral.2011.03.178, 21439330.
    • (2011) Antiviral Res , vol.90 , Issue.3 , pp. 164-167
    • Garrido, C.1    Soriano, V.2    Geretti, A.M.3    Zahonero, N.4    Garcia, S.5    Booth, C.6    Gutierrez, F.7    Viciana, I.8    de Mendoza, C.9
  • 77
    • 84860654622 scopus 로고    scopus 로고
    • Dolutegravir: a new integrase inhibitor in development
    • O' Neal R. Dolutegravir: a new integrase inhibitor in development. , http://www.sfaf.org/hiv-info/hot-topics/beta/2011-beta-winterspring-drug-watch.pdf
    • O' Neal, R.1
  • 78
    • 84860686654 scopus 로고    scopus 로고
    • Early studies demonstrate potent activity and safety of experimental integrase inhibitor S/GSK1265744
    • Highleyman L. Early studies demonstrate potent activity and safety of experimental integrase inhibitor S/GSK1265744. , http://www.hivandhepatitis.com/2009icr/icaac/docs/092209_a.html
    • Highleyman, L.1
  • 79
    • 0029017919 scopus 로고
    • Catalytic domain of human immunodeficiency virus type 1 integrase: identification of a soluble mutant by systematic replacement of hydrophobic residues
    • 10.1073/pnas.92.13.6057, 41641, 7597080
    • Jenkins TM, Hickman AB, Dyda F, Ghirlando R, Davies DR, Craigie R. Catalytic domain of human immunodeficiency virus type 1 integrase: identification of a soluble mutant by systematic replacement of hydrophobic residues. Proc Natl Acad Sci USA 1995, 92(13):6057-6061. 10.1073/pnas.92.13.6057, 41641, 7597080.
    • (1995) Proc Natl Acad Sci USA , vol.92 , Issue.13 , pp. 6057-6061
    • Jenkins, T.M.1    Hickman, A.B.2    Dyda, F.3    Ghirlando, R.4    Davies, D.R.5    Craigie, R.6
  • 80
    • 0029980485 scopus 로고    scopus 로고
    • A soluble active mutant of HIV-1 integrase: involvement of both the core and carboxyl-terminal domains in multimerization
    • 10.1074/jbc.271.13.7712, 8631811
    • Jenkins TM, Engelman A, Ghirlando R, Craigie R. A soluble active mutant of HIV-1 integrase: involvement of both the core and carboxyl-terminal domains in multimerization. J Biol Chem 1996, 271(13):7712-7718. 10.1074/jbc.271.13.7712, 8631811.
    • (1996) J Biol Chem , vol.271 , Issue.13 , pp. 7712-7718
    • Jenkins, T.M.1    Engelman, A.2    Ghirlando, R.3    Craigie, R.4
  • 81
    • 0028584269 scopus 로고
    • Crystal structure of the catalytic domain of HIV-1 integrase: similarity to other polynucleotidyl transferases
    • 10.1126/science.7801124, 7801124
    • Dyda F, Hickman AB, Jenkins TM, Engelman A, Craigie R, Davies DR. Crystal structure of the catalytic domain of HIV-1 integrase: similarity to other polynucleotidyl transferases. Science 1994, 266(5193):1981-1986. 10.1126/science.7801124, 7801124.
    • (1994) Science , vol.266 , Issue.5193 , pp. 1981-1986
    • Dyda, F.1    Hickman, A.B.2    Jenkins, T.M.3    Engelman, A.4    Craigie, R.5    Davies, D.R.6
  • 82
    • 70049117341 scopus 로고    scopus 로고
    • Structural basis for functional tetramerization of lentiviral integrase
    • 10.1371/journal.ppat.1000515, 2705190, 19609359
    • Hare S, Di Nunzio F, Labeja A, Wang J, Engelman A, Cherepanov P. Structural basis for functional tetramerization of lentiviral integrase. PLoS Pathog 2009, 5(7):e1000515. 10.1371/journal.ppat.1000515, 2705190, 19609359.
    • (2009) PLoS Pathog , vol.5 , Issue.7
    • Hare, S.1    Di Nunzio, F.2    Labeja, A.3    Wang, J.4    Engelman, A.5    Cherepanov, P.6
  • 83
    • 77949365510 scopus 로고    scopus 로고
    • Retroviral intasome assembly and inhibition of DNA strand transfer
    • 10.1038/nature08784, 2837123, 20118915
    • Hare S, Gupta SS, Valkov E, Engelman A, Cherepanov P. Retroviral intasome assembly and inhibition of DNA strand transfer. Nature 2010, 464(7286):232-236. 10.1038/nature08784, 2837123, 20118915.
    • (2010) Nature , vol.464 , Issue.7286 , pp. 232-236
    • Hare, S.1    Gupta, S.S.2    Valkov, E.3    Engelman, A.4    Cherepanov, P.5
  • 84
    • 78650533230 scopus 로고    scopus 로고
    • Molecular mechanisms of retroviral integrase inhibition and the evolution of viral resistance
    • 10.1073/pnas.1010246107, 2993412, 21030679
    • Hare S, Vos AM, Clayton RF, Thuring JW, Cummings MD, Cherepanov P. Molecular mechanisms of retroviral integrase inhibition and the evolution of viral resistance. Proc Natl Acad Sci USA 2010, 107(46):20057-20062. 10.1073/pnas.1010246107, 2993412, 21030679.
    • (2010) Proc Natl Acad Sci USA , vol.107 , Issue.46 , pp. 20057-20062
    • Hare, S.1    Vos, A.M.2    Clayton, R.F.3    Thuring, J.W.4    Cummings, M.D.5    Cherepanov, P.6
  • 85
    • 77957670046 scopus 로고    scopus 로고
    • Structure-based modeling of the functional HIV-1 intasome and its inhibition
    • 10.1073/pnas.1002346107, 2936642, 20733078
    • Krishnan L, Li X, Naraharisetty HL, Hare S, Cherepanov P, Engelman A. Structure-based modeling of the functional HIV-1 intasome and its inhibition. Proc Natl Acad Sci USA 2010, 107(36):15910-15915. 10.1073/pnas.1002346107, 2936642, 20733078.
    • (2010) Proc Natl Acad Sci USA , vol.107 , Issue.36 , pp. 15910-15915
    • Krishnan, L.1    Li, X.2    Naraharisetty, H.L.3    Hare, S.4    Cherepanov, P.5    Engelman, A.6
  • 86
    • 78149434355 scopus 로고    scopus 로고
    • The mechanism of retroviral integration from X-ray structures of its key intermediates
    • 10.1038/nature09517, 2999894, 21068843
    • Maertens GN, Hare S, Cherepanov P. The mechanism of retroviral integration from X-ray structures of its key intermediates. Nature 2010, 468(7321):326-329. 10.1038/nature09517, 2999894, 21068843.
    • (2010) Nature , vol.468 , Issue.7321 , pp. 326-329
    • Maertens, G.N.1    Hare, S.2    Cherepanov, P.3
  • 87
    • 80455178762 scopus 로고    scopus 로고
    • FRET analysis reveals distinct conformations of IN tetramers in the presence of viral DNA or LEDGF/p75
    • 10.1093/nar/gkr581, 3203615, 21771857
    • Kessl JJ, Li M, Ignatov M, Shkriabai N, Eidahl JO, Feng L, Musier-Forsyth K, Craigie R, Kvaratskhelia M. FRET analysis reveals distinct conformations of IN tetramers in the presence of viral DNA or LEDGF/p75. Nucleic Acids Res 2011, 39(20):9009-9022. 10.1093/nar/gkr581, 3203615, 21771857.
    • (2011) Nucleic Acids Res , vol.39 , Issue.20 , pp. 9009-9022
    • Kessl, J.J.1    Li, M.2    Ignatov, M.3    Shkriabai, N.4    Eidahl, J.O.5    Feng, L.6    Musier-Forsyth, K.7    Craigie, R.8    Kvaratskhelia, M.9
  • 88
    • 79952070221 scopus 로고    scopus 로고
    • Structural biology of retroviral DNA integration
    • 10.1016/j.virol.2010.12.008, 21216426
    • Li X, Krishnan L, Cherepanov P, Engelman A. Structural biology of retroviral DNA integration. Virology 2011, 411(2):194-205. 10.1016/j.virol.2010.12.008, 21216426.
    • (2011) Virology , vol.411 , Issue.2 , pp. 194-205
    • Li, X.1    Krishnan, L.2    Cherepanov, P.3    Engelman, A.4
  • 89
    • 79953124784 scopus 로고    scopus 로고
    • Structural insights into the retroviral DNA integration apparatus
    • 10.1016/j.sbi.2010.12.005, 21277766
    • Cherepanov P, Maertens GN, Hare S. Structural insights into the retroviral DNA integration apparatus. Curr Opin Struct Biol 2011, 21(2):249-256. 10.1016/j.sbi.2010.12.005, 21277766.
    • (2011) Curr Opin Struct Biol , vol.21 , Issue.2 , pp. 249-256
    • Cherepanov, P.1    Maertens, G.N.2    Hare, S.3
  • 90
    • 6444241385 scopus 로고    scopus 로고
    • A structure-information approach to the prediction of biological activities and properties
    • 10.1002/cbdv.200490010, 17191786
    • Hall LH. A structure-information approach to the prediction of biological activities and properties. Chem Biodivers 2004, 1(1):183-201. 10.1002/cbdv.200490010, 17191786.
    • (2004) Chem Biodivers , vol.1 , Issue.1 , pp. 183-201
    • Hall, L.H.1
  • 91
    • 79960562727 scopus 로고    scopus 로고
    • Multi-target QSAR modelling in the analysis and design of HIV-HCV co-inhibitors: an in-silico study
    • 10.1186/1471-2105-12-294, 3167801, 21774796
    • Liu Q, Zhou H, Liu L, Chen X, Zhu R, Cao Z. Multi-target QSAR modelling in the analysis and design of HIV-HCV co-inhibitors: an in-silico study. BMC Bioinformatics 2011, 12:294. 10.1186/1471-2105-12-294, 3167801, 21774796.
    • (2011) BMC Bioinformatics , vol.12 , pp. 294
    • Liu, Q.1    Zhou, H.2    Liu, L.3    Chen, X.4    Zhu, R.5    Cao, Z.6
  • 92
    • 84455192537 scopus 로고    scopus 로고
    • Molecular dynamics approaches estimate the binding energy of HIV-1 integrase inhibitors and correlate with in vitro activity
    • 10.1128/AAC.05292-11, 22037850
    • Johnson BC, Métifiot M, Pommier Y, Hughes SH. Molecular dynamics approaches estimate the binding energy of HIV-1 integrase inhibitors and correlate with in vitro activity. Antimicrob Agents Chemother 2012, 56(1):411-419. 10.1128/AAC.05292-11, 22037850.
    • (2012) Antimicrob Agents Chemother , vol.56 , Issue.1 , pp. 411-419
    • Johnson, B.C.1    Métifiot, M.2    Pommier, Y.3    Hughes, S.H.4
  • 93
    • 77954682878 scopus 로고    scopus 로고
    • Computer tools in the discovery of HIV-1 integrase inhibitors
    • 10.4155/fmc.10.193, 21426160
    • Liao C, Nicklaus MC. Computer tools in the discovery of HIV-1 integrase inhibitors. Future Med Chem 2010, 2(7):1123-1140. 10.4155/fmc.10.193, 21426160.
    • (2010) Future Med Chem , vol.2 , Issue.7 , pp. 1123-1140
    • Liao, C.1    Nicklaus, M.C.2
  • 94
    • 84860654618 scopus 로고    scopus 로고
    • Discovery of MK-0536: A potential second-generation HIV-1 integrase strand transfer inhibitor with a high genetic barrier to mutation
    • Hoboken, NJ, USA: John Wiley & Sons, Inc, Kazmierski WM
    • Egbertson MS, Wai JS, Cameron M, Hoerrner RS. Discovery of MK-0536: A potential second-generation HIV-1 integrase strand transfer inhibitor with a high genetic barrier to mutation. Antiviral Drugs: From Basic Discovery through Clinical Trials 2011, Hoboken, NJ, USA: John Wiley & Sons, Inc, Kazmierski WM.
    • (2011) Antiviral Drugs: From Basic Discovery through Clinical Trials
    • Egbertson, M.S.1    Wai, J.S.2    Cameron, M.3    Hoerrner, R.S.4
  • 96
    • 84860681015 scopus 로고    scopus 로고
    • Terephthalamate compounds and compositions, and their use as HIV integrase inhibitors
    • He Y, Wang Z, Wu B, IRM LLC. Terephthalamate compounds and compositions, and their use as HIV integrase inhibitors. , http://www.faqs.org/patents/app/20100016379
    • He, Y.1    Wang, Z.2    Wu, B.3    IRM, L.L.C.4
  • 99
    • 80955179970 scopus 로고    scopus 로고
    • Pharmacophore development and docking studies of the hiv-1 integrase inhibitors derived from N-methylpyrimidones, dihydroxypyrimidines, and bicyclic pyrimidinones
    • 10.1111/j.1747-0285.2011.01130.x, 21518263
    • Telvekar VN, Patel KN. Pharmacophore development and docking studies of the hiv-1 integrase inhibitors derived from N-methylpyrimidones, dihydroxypyrimidines, and bicyclic pyrimidinones. Chem Biol Drug Des 2011, 78(1):150-160. 10.1111/j.1747-0285.2011.01130.x, 21518263.
    • (2011) Chem Biol Drug Des , vol.78 , Issue.1 , pp. 150-160
    • Telvekar, V.N.1    Patel, K.N.2
  • 102
    • 79954612735 scopus 로고    scopus 로고
    • Simplified molecular input-line entry system and International Chemical Identifier in the QSAR analysis of styrylquinoline derivatives as HIV-1 integrase inhibitors
    • 10.1111/j.1747-0285.2011.01109.x, 21352501
    • Toropova AP, Toropov AA, Benfenati E, Gini G. Simplified molecular input-line entry system and International Chemical Identifier in the QSAR analysis of styrylquinoline derivatives as HIV-1 integrase inhibitors. Chem Biol Drug Des 2011, 77(5):343-360. 10.1111/j.1747-0285.2011.01109.x, 21352501.
    • (2011) Chem Biol Drug Des , vol.77 , Issue.5 , pp. 343-360
    • Toropova, A.P.1    Toropov, A.A.2    Benfenati, E.3    Gini, G.4
  • 105
    • 79959695256 scopus 로고    scopus 로고
    • The role of unintegrated DNA in HIV infection
    • 10.1186/1742-4690-8-52, 3148978, 21722380
    • Sloan RD, Wainberg MA. The role of unintegrated DNA in HIV infection. Retrovirology 2011, 8:52. 10.1186/1742-4690-8-52, 3148978, 21722380.
    • (2011) Retrovirology , vol.8 , pp. 52
    • Sloan, R.D.1    Wainberg, M.A.2
  • 108
    • 80052498633 scopus 로고    scopus 로고
    • Inhibition of HIV-1 integration in ex vivo-infected CD4 T cells from elite controllers
    • 10.1128/JVI.05327-11, 3165766, 21734042
    • Buzon MJ, Seiss K, Weiss R, Brass AL, Rosenberg ES, Pereyra F, Yu XG, Lichterfeld M. Inhibition of HIV-1 integration in ex vivo-infected CD4 T cells from elite controllers. J Virol 2011, 85(18):9646-9650. 10.1128/JVI.05327-11, 3165766, 21734042.
    • (2011) J Virol , vol.85 , Issue.18 , pp. 9646-9650
    • Buzon, M.J.1    Seiss, K.2    Weiss, R.3    Brass, A.L.4    Rosenberg, E.S.5    Pereyra, F.6    Yu, X.G.7    Lichterfeld, M.8
  • 110
    • 79960377787 scopus 로고    scopus 로고
    • In vitro DNA tethering of HIV-1 integrase by the transcriptional coactivator LEDGF/p75
    • 10.1016/j.jmb.2011.03.073, 21763490
    • McNeely M, Hendrix J, Busschots K, Boons E, Deleersnijder A, Gerard M, Christ F, Debyser Z. In vitro DNA tethering of HIV-1 integrase by the transcriptional coactivator LEDGF/p75. J Mol Biol 2011, 410(5):811-830. 10.1016/j.jmb.2011.03.073, 21763490.
    • (2011) J Mol Biol , vol.410 , Issue.5 , pp. 811-830
    • McNeely, M.1    Hendrix, J.2    Busschots, K.3    Boons, E.4    Deleersnijder, A.5    Gerard, M.6    Christ, F.7    Debyser, Z.8
  • 111
    • 77958015795 scopus 로고    scopus 로고
    • Small molecules targeting the interaction between HIV-1 integrase and LEDGF/p75 cofactor
    • 10.1016/j.bmc.2010.08.051, 20850978
    • De Luca L, Ferro S, Gitto R, Barreca ML, Agnello S, Christ F, Debyser Z, Chimirri A. Small molecules targeting the interaction between HIV-1 integrase and LEDGF/p75 cofactor. Bioorg Med Chem 2010, 18(21):7515-7521. 10.1016/j.bmc.2010.08.051, 20850978.
    • (2010) Bioorg Med Chem , vol.18 , Issue.21 , pp. 7515-7521
    • De Luca, L.1    Ferro, S.2    Gitto, R.3    Barreca, M.L.4    Agnello, S.5    Christ, F.6    Debyser, Z.7    Chimirri, A.8
  • 112
    • 80052401667 scopus 로고    scopus 로고
    • Association of polymorphisms in the LEDGF/p75 gene (PSIP1) with susceptibility to HIV-1 infection and disease progression
    • 10.1097/QAD.0b013e328349c693, 21681054
    • Madlala P, Gijsbers R, Christ F, Hombrouck A, Werner L, Mlisana K, An P, Abdool Karim SS, Winkler CA, Debyser Z, Ndung'u T. Association of polymorphisms in the LEDGF/p75 gene (PSIP1) with susceptibility to HIV-1 infection and disease progression. AIDS 2011, 25(14):1711-1719. 10.1097/QAD.0b013e328349c693, 21681054.
    • (2011) AIDS , vol.25 , Issue.14 , pp. 1711-1719
    • Madlala, P.1    Gijsbers, R.2    Christ, F.3    Hombrouck, A.4    Werner, L.5    Mlisana, K.6    An, P.7    Abdool Karim, S.S.8    Winkler, C.A.9    Debyser, Z.10    Ndung'u, T.11
  • 113
    • 79952588405 scopus 로고    scopus 로고
    • LEDGF dominant interference proteins demonstrate prenuclear exposure of HIV-1 integrase and synergize with LEDGF depletion to destroy viral infectivity
    • 10.1128/JVI.01295-10, 3067863, 21270171
    • Meehan AM, Saenz DT, Morrison J, Hu C, Peretz M, Poeschla EM. LEDGF dominant interference proteins demonstrate prenuclear exposure of HIV-1 integrase and synergize with LEDGF depletion to destroy viral infectivity. J Virol 2011, 85(7):3570-3583. 10.1128/JVI.01295-10, 3067863, 21270171.
    • (2011) J Virol , vol.85 , Issue.7 , pp. 3570-3583
    • Meehan, A.M.1    Saenz, D.T.2    Morrison, J.3    Hu, C.4    Peretz, M.5    Poeschla, E.M.6
  • 114
    • 79960465042 scopus 로고    scopus 로고
    • Inhibition of the interaction between HIV-1 integrase and its cofactor LEDGF/p75: a promising approach in anti-retroviral therapy
    • De Luca L, Ferro S, Morreale F, Chimirri A. Inhibition of the interaction between HIV-1 integrase and its cofactor LEDGF/p75: a promising approach in anti-retroviral therapy. Mini Rev Med Chem 2011, 11(8):714-727.
    • (2011) Mini Rev Med Chem , vol.11 , Issue.8 , pp. 714-727
    • De Luca, L.1    Ferro, S.2    Morreale, F.3    Chimirri, A.4
  • 117
    • 79959741307 scopus 로고    scopus 로고
    • Inhibitors of the interactions between HIV-1 IN and the cofactor LEDGF/p75
    • 10.1002/cmdc.201100071, 21506277
    • De Luca L, Ferro S, Morreale F, De Grazia S, Chimirri A. Inhibitors of the interactions between HIV-1 IN and the cofactor LEDGF/p75. ChemMedChem 2011, 6(7):1184-1191. 10.1002/cmdc.201100071, 21506277.
    • (2011) ChemMedChem , vol.6 , Issue.7 , pp. 1184-1191
    • De Luca, L.1    Ferro, S.2    Morreale, F.3    De Grazia, S.4    Chimirri, A.5
  • 118
    • 78651481692 scopus 로고    scopus 로고
    • N-3 hydroxylation of pyrimidine-2,4-diones yields dual inhibitors of HIV reverse transcriptase and integrase
    • 10.1021/ml1002162, 3074239, 21499541
    • Tang J, Maddali K, Dreis CD, Sham YY, Vince R, Pommier Y, Wang Z. N-3 hydroxylation of pyrimidine-2,4-diones yields dual inhibitors of HIV reverse transcriptase and integrase. ACS Med Chem Lett 2011, 2(1):63-67. 10.1021/ml1002162, 3074239, 21499541.
    • (2011) ACS Med Chem Lett , vol.2 , Issue.1 , pp. 63-67
    • Tang, J.1    Maddali, K.2    Dreis, C.D.3    Sham, Y.Y.4    Vince, R.5    Pommier, Y.6    Wang, Z.7
  • 119
    • 77953127859 scopus 로고    scopus 로고
    • Pharmacophore and structure-activity relationships of integrase inhibition within a dual inhibitor scaffold of HIV reverse transcriptase and integrase
    • 10.1016/j.bmc.2010.05.004, 20576573
    • Wang Z, Tang J, Salomon CE, Dreis CD, Vince R. Pharmacophore and structure-activity relationships of integrase inhibition within a dual inhibitor scaffold of HIV reverse transcriptase and integrase. Bioorg Med Chem 2010, 18(12):4202-4211. 10.1016/j.bmc.2010.05.004, 20576573.
    • (2010) Bioorg Med Chem , vol.18 , Issue.12 , pp. 4202-4211
    • Wang, Z.1    Tang, J.2    Salomon, C.E.3    Dreis, C.D.4    Vince, R.5
  • 120
    • 79961078738 scopus 로고    scopus 로고
    • Diketo acids derivatives as dual inhibitors of human immunodeficiency virus type 1 integrase and the reverse transcriptase RNase H domain
    • 10.2174/092986711796504619, 21728968
    • Di Santo R. Diketo acids derivatives as dual inhibitors of human immunodeficiency virus type 1 integrase and the reverse transcriptase RNase H domain. Curr Med Chem 2011, 18(22):3335-3342. 10.2174/092986711796504619, 21728968.
    • (2011) Curr Med Chem , vol.18 , Issue.22 , pp. 3335-3342
    • Di Santo, R.1
  • 121
    • 79952711748 scopus 로고    scopus 로고
    • Subtype diversity associated with the development of HIV-1 resistance to integrase inhibitors
    • 10.1002/jmv.22047, 21360548
    • Brenner BG, Lowe M, Moisi D, Hardy I, Gagnon S, Charest H, Baril JG, Wainberg MA, Roger M. Subtype diversity associated with the development of HIV-1 resistance to integrase inhibitors. J Med Virol 2011, 83(5):751-759. 10.1002/jmv.22047, 21360548.
    • (2011) J Med Virol , vol.83 , Issue.5 , pp. 751-759
    • Brenner, B.G.1    Lowe, M.2    Moisi, D.3    Hardy, I.4    Gagnon, S.5    Charest, H.6    Baril, J.G.7    Wainberg, M.A.8    Roger, M.9
  • 122
    • 58549116531 scopus 로고    scopus 로고
    • Implications of HIV-1 M group polymorphisms on integrase inhibitor efficacy and resistance: genetic and structural in silico analyses
    • 10.1021/bi8019349, 19090674
    • Loizidou EZ, Kousiappa I, Zeinalipour-Yazdi CD, van de Vijver DA, Kostrikis LG. Implications of HIV-1 M group polymorphisms on integrase inhibitor efficacy and resistance: genetic and structural in silico analyses. Biochemistry 2009, 48(1):4-6. 10.1021/bi8019349, 19090674.
    • (2009) Biochemistry , vol.48 , Issue.1 , pp. 4-6
    • Loizidou, E.Z.1    Kousiappa, I.2    Zeinalipour-Yazdi, C.D.3    van de Vijver, D.A.4    Kostrikis, L.G.5


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.